KRAS and neoplasm: Interestingly, PDAC hetero-transplants that possess mutant K-Ras and Akt2 amplification are extremely responsive to co-treatment with dactolisib (BEZ235) and panobinostat, resulting in the inhibition of tumor growth (Venkannagari et al., 2012).